1-3 of 3
Shivani K Mhatre, MSc
Close
Sort by
Journal Articles

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

B. Douglas Smith, MD, Jun Liu, PhD, Dominick Latremouille-Viau, MSc, Zhou Zhou, MSc, Annie Guerin, MSc, Daniel Fernandez, MA, Dingdong Yi, BS, Xufei Wang, MA, Eric Q Wu, PhD, Shivani K Mhatre, MSc, Christopher H Keir, MD, Lei Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2618.
https://doi.org/10.1182/blood.V124.21.2618.2618
Published: 2014
Journal Articles

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

B. Douglas Smith, MD, Jun Liu, PhD, Dominick Latremouille-Viau, MSc, Zhou Zhou, MSc, Annie Guerin, MSc, Daniel Fernandez, MA, Dingdong Yi, BS, Xufei Wang, MA, Eric Q Wu, PhD, Shivani K Mhatre, MSc, Christopher H Keir, MD, Lei Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1293.
https://doi.org/10.1182/blood.V124.21.1293.1293
Published: 2014
Journal Articles

Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Annie Guerin, MSc, Cindy Revol, MPH, Agnihotram V. Ramanakumar, PhD, Rebekah Foster, BA, Eric Qiong Wu, PhD, Shivani K Mhatre, MSc, Lei Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1304.
https://doi.org/10.1182/blood.V124.21.1304.1304
Published: 2014